Related references
Note: Only part of the references are listed.Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy
Rui Huang et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
Rod S. Taylor et al.
GASTROENTEROLOGY (2020)
Advances in non-invasive assessment of hepatic fibrosis
Rohit Loomba et al.
GUT (2020)
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
Beth A. Davison et al.
JOURNAL OF HEPATOLOGY (2020)
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease
Arjun N. A. Jayaswal et al.
LIVER INTERNATIONAL (2020)
Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis
Naga Chalasani et al.
LIVER INTERNATIONAL (2019)
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
Ankur Srivastava et al.
JOURNAL OF HEPATOLOGY (2019)
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2019)
Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease
Katharina Staufer et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
Vlad Ratziu et al.
CONTEMPORARY CLINICAL TRIALS (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
Rohit Loomba et al.
GASTROENTEROLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
David E. Kleiner et al.
JAMA NETWORK OPEN (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
Mazen Noureddin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Mehmet Sayiner et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease
Katharine M. Irvine et al.
LIVER INTERNATIONAL (2016)
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
William N. Hannah et al.
CLINICS IN LIVER DISEASE (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?
Jun L. Chin et al.
FRONTIERS IN PHARMACOLOGY (2016)
Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease
Elif Dincses et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson et al.
JOURNAL OF HEPATOLOGY (2015)
Noninvasive Evaluation of Liver Fibrosis Using Real-time Tissue Elastography and Transient Elastography (FibroScan)
Fankun Meng et al.
JOURNAL OF ULTRASOUND IN MEDICINE (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Bile acid nuclear receptor FXR and digestive system diseases
Lili Ding et al.
ACTA PHARMACEUTICA SINICA B (2015)
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
Rajarshi Banerjee et al.
JOURNAL OF HEPATOLOGY (2014)
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2013)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease
Sudeep Tanwar et al.
HEPATOLOGY (2013)
The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values
Ralf Lichtinghagen et al.
JOURNAL OF HEPATOLOGY (2013)
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
Raffaella M. Gadaleta et al.
GUT (2011)
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Amy G. Shah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo et al.
HEPATOLOGY (2007)
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
V Ratziu et al.
BMC GASTROENTEROLOGY (2006)
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
V Ratziu et al.
GASTROENTEROLOGY (2005)
Transient elastography: A new noninvasive method for assessment of hepatic fibrosis
L Sandrin et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2003)
Share Paper
